Last reviewed 2026-04-20 · How we verify

Niravam

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Drowsiness
• Lightheadedness
• Sedation
• Concentration difficulties
• Irritability
• Fatigue
• Slurred speech
• Loss of coordination
• Transient amnesia or memory impairment
• Anorexia
• Musculoskeletal weakness
• Pruritus

Serious adverse events

• Seizures
• Hallucinations
• Depersonalization
• Dystonia
• Jaundice
• Elevated hepatic enzymes
• Elevated bilirubin
• Diplopia
• Dysarthria
• Withdrawal seizures

Key clinical trials

• An Open Label, Single Dose, Randomized, Active Comparator, Quantitative Electroencephalogram Crossover Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Intravenous Midazolam a (Phase 1)
• An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizu (Phase 3)
• Randomized, Double-blind, Placebo-controlled Study of a Benzodiazepine vs Placebo on Functional Magnetic Resonance Imaging (fMRI) of the Brain, and on Behavioral/Clinical Measures in Patients With Gen (Phase 4)
• Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 2 (NA)
• Effect of Preoperative Alprazolam on the Success of Inferior Alveolar Nerve Block for Teeth With Irreversible Pulpitis (Phase 4)
• Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Trial With Single Dosageof Two Oral Preparations Containing 2 mg of Alprazolam (Zamoprax GlaxoSmithKline México, S.A. de C.V. v (Phase 1)
• MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers (Phase 1)
• NCT01546896 (Phase 4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.